Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial

Andrew Zolopa, Andrew Cheng, Jeffrey Enejosa et al.|The Journal of Infectious Diseases|2010

Cited by 114